Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
Treatment naive or have received prior standard therapy appropriate for tumor type and stage
Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate organ function
Primary central nervous system (CNS) tumors
Active, untreated brain metastases
Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
Single group
RMC-6236
DrugOral Tablets
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs
Number of Participants with Dose-Limiting Toxicity (DLT)
Maximum Observed Blood Concentration (Cmax) of RMC-6236
Time to Reach Maximum Blood Concentration (Tmax) of RMC-6236
Area Under Blood Concentration Time Curve (AUC) of RMC-6236
Elimination Half-Life of RMC-6236 (t1/2)
Click on the lead sponsor to view all of their trials.
